A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa)

被引：0
|
作者：
Kilari, D. [1 ]
Guancial, E. [2 ]
Sahasrabudhe, D. [2 ]
Bylow, K. [1 ]
Sievert, L. [2 ]
Schaffer, K. [2 ]
Riese, M. [1 ]
Burfeind, J. [1 ]
Musto, K. [1 ]
Feng, C. [3 ]
Messing, E. [4 ]
Mohile, S. [2 ]
Fung, C. [2 ]
机构：
[1] Med Coll Wisconsin, Froedtert Hosp, Med, Milwaukee, WI 53226 USA
[2] Univ Rochester, Med, Rochester, NY USA
[3] Univ Rochester, Biostat, Rochester, NY USA
[4] Univ Rochester, Urol, Rochester, NY USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
808P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study
    Gao, Xin
    Smith, Matthew Raymond
    Scher, Howard I.
    Verholen, Frank
    Adorjan, Patrick
    Dissanayake, Manjari
    Laccetti, Andrew Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial
    Lin, J.
    Beer, T. M.
    Ryan, C. J.
    Mathew, P.
    Wilding, G.
    Morris, M.
    Callahan, J. A.
    Gordon, G.
    Reich, S.
    Carducci, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
    Calcagno, Fabien
    Mouillet, Guillaume
    Adotevi, Olivier
    Maurina, Tristan
    Nguyen, Thierry
    Montcuquet, Philippe
    Curtit, E.
    Kleinclauss, F.
    Pivot, Xavier
    Borg, Christophe
    Thiery-Vuillemin, Antoine
    MEDICAL ONCOLOGY, 2016, 33 (08)
  • [24] Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
    Fabien Calcagno
    Guillaume Mouillet
    Olivier Adotevi
    Tristan Maurina
    Thierry Nguyen
    Philippe Montcuquet
    E. Curtit
    F. Kleinclauss
    Xavier Pivot
    Christophe Borg
    Antoine Thiery-Vuillemin
    Medical Oncology, 2016, 33
  • [25] A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naive prostate cancer (mHNPC): ZZFIRST.
    Mateo, Joaquin
    Borque, Angel
    Castellano, Daniel E.
    Castro, Elena
    Climent Duran, Miguel Angel A.
    Font, Albert
    Lorente, David
    Mellado, Begona
    Rodriguez-Vida, Alejo
    Cuadras, Merce
    Planas, Jacques
    Casanova Salas, Irene
    Cordoba, Sarai
    Gonzalez, Lucila
    Martinez de Falcon, Marta
    Fernandez, Melissa
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Perez-Lopez, Raquel
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] 13-cis retinoic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients:: Report of a phase II randomized study
    Ferrari, AC
    Stone, N
    Stock, R
    Bednar, M
    Esseesse, I
    Singh, H
    Baldwin, Y
    Mandeli, J
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 538 - 544
  • [27] A phase II, open-label, single-arm, efficacy, and safety study of MDV3100 in patients with hormone-naive prostate cancer
    Baskin-Bey, E. S.
    Holtkamp, G. M.
    Smith, M. R.
    Ouatas, T.
    Phung, D.
    Tombal, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [28] UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC).
    Azad, Arun
    Dhiantravan, Nattakorn
    Emmett, Louise
    Joshua, Anthony M.
    Vela, Ian
    Pattison, David A.
    Francis, Roslyn J.
    Williams, Scott
    Sandhu, Shahneen Kaur
    Davis, Ian D.
    Neha, Nitika
    Bressel, Mathias
    Murphy, Declan G.
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [29] Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial
    Burgess, Earle F.
    Grigg, Claud M.
    Boselli, Danielle
    Symanowski, James T.
    Golshayan, Alireza
    Graham, David L.
    Osei-Boateng, Kwabena
    Gavini, Nagajyothi
    Zhu, Jiang
    Brown, Landon C.
    Norek, Sarah
    Begic, Xhevahire J.
    Raghavan, Derek
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
  • [30] A multi-centre study comparing between hormonal therapy and chemohormonal therapy in treating Chinese men with metastatic hormone-naive prostate cancer
    Teoh, Jeremy Yuen Chun
    Poon, Darren Ming Chun
    Lam, Daisy
    Chan, Tim
    Chan, Michelle
    Lee, Ka Chai
    Law, Snow
    Chan, Kuen
    Cheng, Nicole M. Y.
    Lai, Kai Ming
    Ng, Chi Fai
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 354 - 355
12345